Vincent Groot

MD, PhD and aspiring surgeon with interest in HPB surgery.

[Vincent Groot @VincGroot]

@clintoptions $SPY

[Vincent Groot @VincGroot]

🚨 Check out our newest study on how recurrence treatment of #PancreaticCancer is influenced by prior treatment

[Annals of Surgical Oncology @AnnSurgOncol]

February Issue: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of #PancreaticDuctalAdenocarcinoma @VincGroot

https://t.co/b6yQgULFZG

@jhatjhmi1
@SyedAAhmad5
@SocSurgOnc

[Vincent Groot @VincGroot]

@sciqst @AnnalsofSurgery @DPCG_official @MarcBesselink @Gio_Marchegiani @IqQ4q @HpbRaku @YouppiePancreas This was a retrospective study, there was no selection of patients for imaging vs routine follow-up (doctor and patient preference). We are conducting the RADAR-panc trial to answer most of these questions, expecting results next year!

https://t.co/luHc9zo1PC

[Vincent Groot @VincGroot]

🚨 New in @AnnalsofSurgery showing ⬆️ survival with routine imaging vs symptomatic follow-up after #pdac resection.

🕵🏼‍♂️Routine imaging also associated with asymptomatic recurrence and recurrence treatment.

@DPCG_official
@MarcBesselink
@Gio_Marchegiani

https://t.co/87mI09HJNL

[Vincent Groot @VincGroot]

@YouppiePancreas @lelecapurso @German_PancClub @EurPancClub @Lguilabert1 @SN_gastro Congrats Mat!

[Vincent Groot @VincGroot]

@MarcBesselink @AmerSurg @IHPBA @EAHPBA @AHPBA @HopkinsMedicine @AndrewMCameron @jhatjhmi1 @P_C_E_ @DPCG_official Living Legend!

[Giovanni Marchegiani @Gio_Marchegiani]

Lung only metastatic PDAC 🫁 Better survival than liver!

In @NatureCancer 🧬 a primary organotropism (pORG) gene set analysis

👮 Lung-avid/liver-averse tumors associated with active tumor immunity / less replication stress 😥

🤌 Your policy!?

https://t.co/s1BLrxF10v

[Vincent Groot @VincGroot]

@Gio_Marchegiani @EAHPBA @MarcBesselink @JAMASurgery @Serrablohpb @sparrelid @BasGrootKoerkam @iisifrigerio @Simone_Aug @IHPBA @hpb_trials @hpb_so Thanks voor promoting our study @Gio_Marchegiani!

[Giovanni Marchegiani @Gio_Marchegiani]

(Let’s keep using this social in the best possible way … ) 🫢

🟠 Recurrence after PDAC resection is sadly a fact

🔵 @EAHPBA study on 333 pts reveals routine imaging in post op 👍 vs. symptomatic FU

💡Prompt access chemo = better survival

https://t.co/cbwMEr2qrG

[Vincent Groot @VincGroot]

🎓 Check out our latest paper in @JAMASurgery!

@YouppiePancreas @hpb_so @HpbRaku

[JAMA Surgery @JAMASurgery]

Routine imaging after pancreatic ductal adenocarcinoma (PDAC) resection was associated with increased recurrence-focused treatment and improved survival in this multicenter study.

https://t.co/d1cpgcdGEu

[Vincent Groot @VincGroot]

🎓 Check out our latest work in @JAMASurgery on postoperative follow-up strategies after surgery for #pancreaticcancer.

In this first prospective international study on this topic, results show that routine post-operative imaging can be beneficial.

https://t.co/i1NJJ3gxvC

[Vincent Groot @VincGroot]

🎓 Protocol of RADAR-PANC has been published! This RCT will be the first to generate high level evidence on the value of recurrence-focused postoperative surveillance in patients after pancreatic cancer resection.

@LoisDaamen @hpb_so @YouppiePancreas

https://t.co/HQmYPJTy0r

[Vincent Groot @VincGroot]

@timpawlik @OhioStateSurg @AlexBlairMD @MSKCancerCenter @hopkinssurgery @OSUCCC_James @OSUWexMed @OhioStateNews @OhioStateMed @SocSurgOnc @AHPBA @isteaus @mary_dillhoff @jcloydmd Well deserved @AlexBlairMD! Go rock their world 💪

[Vincent Groot @VincGroot]

To highlight our special issue, we (@LoisDaamen & @IqQ4q) wrote an editorial named: Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence.

Want to read more? Link: https://t.co/QAhrYn3mRm

[Vincent Groot @VincGroot]

🏥Substantial new contribution by friends and former @HopkinsMedicine colleagues @BradReames & @AEjaz85 to our special issue in the @JCM_MDPI.

🎓Read their systematic review on recurrence patterns after resection of IPMN through this link: https://t.co/G7SCh3ujTt.

@LoisDaamen

[Vincent Groot @VincGroot]

🎓 Thank you @FelixAberer for a new and important contribution to our special issue in the @JCM_MDPI, elucidating the impact of diabetes mellitus on the outcomes of patients undergoing pancreatic surgery.

Article link: https://t.co/PZmJ0Wzw6G

@LoisDaamen & @IqQ4q

[Vincent Groot @VincGroot]

🚨 Happy to share the first contribution to our special issue "Pancreatic Cancer: Recent Advances and Future Challenges" in the @JCM_MDPI.

Article link: https://t.co/4fJMg4GzFr.
Contribute your own pancreatic research through: https://t.co/9oTOldnBev.

@LoisDaamen & @IqQ4q

[Vincent Groot @VincGroot]

🚨Check out below our highlighted article by @ejsotweets on predicting post-recurrence survival after #pancreaticcancer resection.

@LoisDaamen @hpb_so @YouppiePancreas @jhatjhmi1

[European Journal of Surgical Oncology @ejsotweets]

Predicting post-recurrence survival for pts with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification @hopkinssurgery @UMCU_Intl

@LoisDaamen @DPCG_official @VincGroot @J_habib1 @bkinnykoester @jhatjhmi1

https://t.co/MDhKYNEKUU

[Vincent Groot @VincGroot]

⬇️⬇️Submit your pancreatic research! ⬇️⬇️

[JCM MDPI @JCM_MDPI]

📢We would like to share with you that Special Issue “Pancreatic Cancer: Recent Advances and Future Challenges” is open for submissions.
👥Guest Editors: @VincGroot , @LoisDaamen & @IqQ4q
👉More info: https://t.co/4BNKGdA6LE
#PancreaticCancer

[Vincent Groot @VincGroot]

We cordially invite you to submit your original or review article on clinical or translational research to this Special Issue through the following link: https://t.co/9oTOldnBev.

@YouppiePancreas @hpb_so

[Vincent Groot @VincGroot]

Dear colleagues,

As Guest Editors (together with @LoisDaamen & @IqQ4q), we are pleased to announce the launch of a new Special Issue entitled: “Pancreatic Cancer: Recent Advances and Future Challenges” to be published in the Journal of Clinical Medicine (@JCM_MDPI, IF 3.9).